Vimta Labs Limited has successfully allotted 34,166 employee stock options under its Employee Stock Option Plan 2021, marking another milestone in its employee incentive program. The ESOP Allotment Committee of the Board of Directors approved this allotment during their meeting held on 09th March 2026.

Share Capital Enhancement

The allotment has resulted in a significant increase in the company's share capital structure. The exercise price for these options was set at ₹2/- per share, matching the face value of the equity shares.

ESOP Plan Details

The shares were allotted under the "Vimta Labs Employee Stock Option Plan 2021" to eligible employees of the company. The distinctive numbers for the newly allotted shares range from 48335190 to 48369355, both inclusive.

Regulatory Compliance and Listing

Vimta Labs Limited has fulfilled its regulatory obligations by informing both BSE Limited and National Stock Exchange of India Limited about this allotment. The company confirmed that the newly allotted shares will rank pari-passu with existing equity shares, ensuring equal rights and privileges for all shareholders.

The company is currently in the process of completing other formalities required for listing these allotted shares on both stock exchanges. The allotment was made pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Previous Approvals and Filings

The company had previously received in-principle listing approvals from both exchanges. BSE Limited provided approval for 6,63,234 equity shares in September 2021, with additional approval for 5,18,260 equity shares in August 2025 following a bonus issue application. Similarly, NSE granted approval for the initial tranche in August 2021 and the additional shares in September 2025.

The allotment reinforces Vimta Labs' commitment to employee participation in the company's growth through structured stock option programs, while maintaining compliance with all regulatory requirements.

VIMTA Labs has reported its financial performance for the third quarter, showing steady profitability with a net profit of ₹176 million. The company's latest results demonstrate consistent operational performance in its core business segments.

Financial Performance Overview

The testing and analytical services company recorded a net profit of ₹176 million for Q3, representing a marginal improvement from the corresponding quarter of the previous year. This performance indicates stable business operations and maintained profitability levels.

| Financial Metric: | Q3 Current Year | Q3 Previous Year | Change || | ---: | :--- | :--- | :--- | | Net Profit: | ₹176 million | ₹175 million | ₹1 million increase |

Business Performance Analysis

VIMTA Labs' Q3 results reflect the company's ability to maintain consistent profitability levels in its specialized testing and analytical services business. The year-on-year comparison shows steady performance with the net profit increasing from ₹175 million to ₹176 million, indicating operational stability.

The company continues to operate in the testing, inspection, and certification services sector, serving various industries including pharmaceuticals, food, environment, and materials testing. This quarter's performance demonstrates the resilience of the company's business model and its capacity to deliver consistent financial results.